IP Library Granted Patent US 9,044,435
Granted Patent B2
US 9,044,435 · App. 14/484,077 · Granted Jun 2, 2015

Pharmaceutical formulation containing gelling agent

Inventors: Curtis Wright (Rockport, MA); Benjamin Oshlack (Boca Raton, FL); Christopher Breder (Bethesda, MD)
Assignees: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.
A61K31/167A61K9/2013A61K9/205A61K9/2054A61K9/0002A61K31/439A61K31/485A61K47/38A61K47/36A61K47/10A61K45/06A61K31/192A61K9/1652A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,044,435
App. No.
14/484,077
Granted
Jun 2, 2015
Kind
B2
Abstract

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Claims (26)

1. A controlled release oral solid dosage form comprising particles comprising:

(i) hydrocodone or a pharmaceutically acceptable salt thereof;

(ii) a gelling agent comprising hydroxypropylmethylcellulose;

(iii) ethylcellulose; and

(iii) a glyceryl ester of a fatty acid;

wherein the particles are overcoated with a controlled release material comprising ethylcellulose;

the oral solid dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient and the oral solid dosage form when subjected to tampering by dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid provides a viscosity of at least about 10 cP.

2. The controlled release oral solid dosage form of claim 1 , providing a viscosity of at least about 60 cP.

3. The controlled release oral solid dosage form of claim 1 , providing a viscosity of at least about 120 cP.

4. The controlled release oral solid dosage form of claim 1 , providing a viscosity of at least about 375 cP.

5. The controlled release oral solid dosage form of claim 1 , providing a viscosity of at least about 2,000 cP.

6. The controlled release oral solid dosage form of claim 1 , providing a viscosity from about 120 cP to about 5,000 cP.

7. The controlled release oral solid dosage form of claim 1 , comprising hydrocodone bitartrate.

8. The controlled release oral solid dosage form of claim 7 , comprising from about 75 ng to about 750 mg hydrocodone bitartrate.

9. The controlled release oral solid dosage form of claim 7 , comprising from about 2 mg to about 50 mg hydrocodone bitartrate.

10. The controlled release oral solid dosage form of claim 1 , in the form of a tablet.

11. The controlled release oral solid dosage form of claim 1 , wherein the particles are in granular form.

12. The controlled release oral solid dosage form of claim 11 , wherein the coated particles are compressed into a tablet.

13. The controlled release oral solid dosage form of claim 12 , wherein the tablet further comprising a pharmaceutically acceptable excipient.

14. The controlled release oral solid dosage form of claim 2 , wherein the ratio of gelling agent to hydrocodone or pharmaceutically acceptable salt thereof is from about 1:40 to about 40:1.

15. The controlled release oral solid dosage form of claim 2 , wherein the aqueous liquid is water.

16. The controlled release oral solid dosage form of claim 2 , wherein the viscosity is provided when the dosage form is subjected to tampering by dissolution in about 1 ml to about 3 ml of aqueous liquid.

17. The controlled release oral solid dosage form of claim 2 , wherein the viscosity is provided when the dosage form is subjected to tampering by dissolution and crushing in the aqueous liquid.

18. The controlled release oral solid dosage form of claim 2 , wherein the viscosity is provided when the dosage form is subjected to tampering by dissolution in the aqueous liquid with heating at a temperature of greater than 45° C.

19. The controlled release oral solid dosage form of claim 2 , further comprising acetaminophen.

20. The controlled release oral solid dosage form of claim 2 , further comprising ibuprofen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048932/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2014
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.
Reel/Frame 033865/0459 →
Continuity (7)
Continuation 14255502 · Apr 17, 2014
Continuation 13726324 · Dec 24, 2012
Continuation 13349449 · Jan 12, 2012
Continuation 12653115 · Dec 8, 2009
Continuation 10214412 · Aug 6, 2002
Provisional Application 60310534 · Aug 6, 2001
Related Publication 20150005333A1 · Jan 1, 2015